scholarly journals Mitochondrial Channels and their Role in Cardioprotection

2021 ◽  
Author(s):  
Keerti Mishra ◽  
Min Luo

Mitochondria play a pivotal role in cardioprotection. The major cardioprotective mechanism is ischemic preconditioning (IpreC), through which short periods of ischemia protect a subsequent prolonged acute ischemic episode. Mitochondria channels, particularly the potassium channels (mitoK) such as ATP-dependent and calcium-activated potassium channels, have been suggested as trigger or end effectors in IpreC. Activators of mitoK are promising therapeutic agents for the treatment of the myocardial injury due to ischemic episodes. In this chapter, we are summarizing our current knowledge on the physiology function of different mitochondrial channels with a focus on the potassium channels and their mechanism in cardioprotection. Furthermore, the currently under development therapy by targeting the mitochondrial channels for the treatment of heart failure are also discussed.

Biochemistry ◽  
1997 ◽  
Vol 36 (7) ◽  
pp. 1943-1952 ◽  
Author(s):  
Alexandra Koschak ◽  
Robert O. Koch ◽  
Jessica Liu ◽  
Gregory J. Kaczorowski ◽  
Peter H. Reinhart ◽  
...  

2015 ◽  
Vol 290 (11) ◽  
pp. 7016-7026 ◽  
Author(s):  
Fu Yi ◽  
Tian-You Ling ◽  
Tong Lu ◽  
Xiao-Li Wang ◽  
Jingchao Li ◽  
...  

2013 ◽  
Vol 30 ◽  
pp. 149-149
Author(s):  
C. Kramer ◽  
A. Kretschmer ◽  
C. Ertelt-Delbridge ◽  
M. Blobner ◽  
H. Fink

Author(s):  
Cheng Liu ◽  
Yanxian Lai ◽  
Jingxian Pei ◽  
Huiling Huang ◽  
Junfang Zhan ◽  
...  

Abstract Context Lower serum concentration of apolipoprotein A-I (ApoA-I) is causally associated with heart failure (HF) risk. ATP-sensitive potassium channels (KATP), as a gating channel coupling vascular reactivity and metabolism with ischemic protection, become a new potential target of management for HF. The KATP gene sequence is highly polymorphic and high degree of genetic heterogeneity. Objective To determine whether ATP-sensitive potassium channels (KATP) variants predict the risks of decreased ApoA-I concentration and its related HF. Design, Patients, Settings A total of 634 subjects, including 317 subjects with decreased ApoA-I concentration (< 120 mg/dL) and 317 counterpart subjects (≥ 120 mg/dL), were retrospectively selected. Methods 5 KATP variants were genotyped through MassARRAY platform. The exosome-derived microRNAs (exo-miRs) expression profiles were identified by next-generation sequencing, and the top 10 DE exo-miRs were verified using qPCR in a validation cohort of 240 subjects with decreased ApoA-I concentration. Results KATP rs141294036 was related to increased risk of lower ApoA-I levels (adjusted OR=1.95, P=0.002) and HF incidence (adjusted OR=2.38, P=0.009), especially HFpEF (adjusted OR=2.13, P=0.015). After median 48.6-months follow-up, participants carrying CC genotype of rs141294036 was associated with elevated HF re-hospitalization risk (adjusted HR=1.91, P=0.005). 36 exo-miRs were significantly differentially expressed between different genotypes of rs141294036 in subjects with lower ApoA-I levels, but only 5 exo-miRs (miR-31-5p, miR-126-5p, miR-106a-5p, miR-378i and miR-181c-5p) were further confirmed. Conclusions The KATP rs141294036 was associated with increased risks of lower ApoA-I levels, HF incidence (especially HFpEF) and HF re-hospitalization, involving in those 5 confirmed exo-miRs and its related metabolic pathways.


Sign in / Sign up

Export Citation Format

Share Document